Get startedLog in
    Picture of ScinoPharm Taiwan logo

    1789 — ScinoPharm Taiwan Cashflow Statement

    0.000.00%
    tw flag iconLast trade - 00:00
    HealthcareBalancedMid CapHigh Flyer
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for ScinoPharm Taiwan, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

    2019
    December 31st
    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line265359302438349
    Depreciation
    Amortisation
    Non-Cash Items-0.502-67.4-35.2-15-25.9
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital116262-139-88.7-553
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Accounts Payable
    Change in Accrued Expenses
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities789946510774231
    Capital Expenditures-103-180-314-243-268
    Purchase of Fixed Assets
    Other Investing Cash Flow Items4.13422244-10.335.1
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Change in Net Intangibles
    Other Investing Cash Flow
    Cash from Investing Activities-98.4242-70-254-233
    Financing Cash Flow Items-1.621.212.35-1.3-1.03
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-1,572-445-413-315-341
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-89875026214-353